Benchmark starts LeMaitre Vascular at Buy

|About: LeMaitre Vascular, Inc. (LMAT)|By:, SA News Editor

Benchmark initiates LeMaitre Vascular (LMAT +2%) at Buy.

"The company's well-established position within the vascular surgeon community, and its focus on niche products that typically do not attract competition from the industry giants, give the company a bit of a home field advantage," analyst Jan Wald says, adding that "10%+ annual revenue growth and a $0.12 annual dividend provides investors with reasons to own the stock."

Price target is $9, representing a 28% upside from Wednesday's close.